The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men .
OBJECTIVES Ageing in men is associated with a gradual decline in serum testosterone levels and a concomitant loss of muscle mass , accumulation of central adiposity , impaired mobility and increased risk of bone fractures .
Whether and rogen treatment might be beneficial in these subjects is still under debate .
We have carried out a systematic review of r and omized controlled trials ( RCTs ) evaluating the effects of testosterone ( T ) administration  to middle-aged and ageing men on body composition , muscle strength , bone density , markers of bone metabolism and serum lipid profile .
Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial.
CONTEXT Patients receiving dialysis commonly experience malnutrition , reduced muscle mass ( sarcopenia ) , and fatigue for which no effective treatment has been identified . Anabolic steroids are known to increase muscle mass and strength in healthy individuals , but their effect on the sarcopenia and fatigue associated with long-term dialysis has not been evaluated . OBJECTIVE To assess the effects of an anabolic steroid , n and rolone decanoate , on lean body mass ( LBM ) , functional status , and quality of life in dialysis patients . DESIGN R and omized , double-blind , placebo-controlled trial conducted between April 1996 and July 1997 . SETTING Hospital-based outpatient dialysis unit . PATIENTS Twenty-nine patients undergoing dialysis for at least 3 months . INTERVENTION N and rolone decanoate , 100 mg ( n = 14 ) , or placebo ( n = 15 ) by intramuscular injection once a week for 6 months . MAIN OUTCOME MEASURES Weight , LBM , fatigue , grip strength , walking and stair-climbing times , and treadmill performance after 3 and 6 months of treatment . RESULTS Lean body mass increased significantly in patients given n and rolone compared with patients given placebo ( mean change [ SD ] , + 4.5 [ 2.3 ] kg ; P<.001 compared with baseline ) . This effect was significantly greater than the change in LBM in the placebo group ( mean change [ SD ] , + 1.9 [ 1.6 ] kg ; P = .003 compared with baseline ; P = .005 compared with n and rolone group ) . Serum creatinine levels increased in the n and rolone group ( + 168 [ 203 ] mmol/L [ 1.9 [ 2.3 ] mg/dL ] ; P = .02 ) but not in the placebo group ( -4.0 [ 177 ] mmol/L [ 0.04 [ 2.0 ] mg/dL ] ; P = .95 ) , suggesting an increase in muscle mass . Time to complete the walking and stair-climbing test decreased from 36.5 to 32.7 seconds in the n and rolone group , while those in the placebo group increased from 38.7 to 42.1 seconds ( P = .05 ) . Peak oxygen consumption increased in the individuals in the n and rolone group who performed treadmill tests , but not to a statistically significant degree . Grip strength did not change in either group . CONCLUSIONS Treatment with n and rolone for 6 months result ed in a significant increase in LBM associated with functional improvement in patients undergoing dialysis
The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men .
OBJECTIVES Ageing in men is associated with a gradual decline in serum testosterone levels and a concomitant loss of muscle mass , accumulation of central adiposity , impaired mobility and increased risk of bone fractures .
Whether and rogen treatment might be beneficial in these subjects is still under debate .
We have carried out a systematic review of r and omized controlled trials ( RCTs ) evaluating the effects of testosterone ( T ) administration  to middle-aged and ageing men on body composition , muscle strength , bone density , markers of bone metabolism and serum lipid profile .